explore -WSS

explore

author：knowledge 2025-10-02 12:02:11 - browse：34

Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications.

The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said. But the weight reductions were smaller than those seen in trials of rival medicines targeting the same GLP-1 pathway, and a high rate of patients experienced side effects and dropped out of the trial.

Pfizer said it would not move twice-daily danuglipron into Phase 3 trials, but that instead it would focus on a once-daily formulation, which is currently undergoing pharmacokinetic studies. Data are expected in the first half of 2024.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Tulsa Race Massacre survivors and attorneys respond to dismissal of lawsuit

entertainment

WSS

Wisconsin governor employs partial veto to fund schools for 4 centuries

Campaign finance charge dropped from case against Sam Bankman

Wisconsin governor employs partial veto to fund schools for 4 centuries

Typhoon Doksuri makes landfall in China after bringing deadly landslides to Philippines

China demands US invite Hong Kong leader to economic meeting, adding to strains over crackdown

Home health providers sue Medicare over payment cuts

explore

explore

entertainment

Wildfire smoke exposes gaps in outdoor worker protections

Campaign finance charge dropped from case against Sam Bankman

Affirmative action in medical school literally saved lives

DeSantis defends odds vs. Trump, despite early poll gap: 'We've worked really hard'

United colonoscopy coverage change 'may cost lives,' doctors say

Recent heat wave in the Mediterranean caused by climate change: Study

DIEP, the 'gold standard' of breast reconstruction, is under threat

Young Chinese opt out of the rat race and pressures at home to pursue global nomad lifestyle

Sports medicine is finally prioritizing gender equality

Medicare wants to send $9 billion to 340B hospitals

explore

Pandemic and All Hazards Preparedness Act needs lean update

ACA's risk program benefits Blue Cross Blue Shield insurers

Doctors in states that ban abortion can still help patients

‘Insidious 5’ topples 'Indiana Jones' before ‘Mission: Impossible’ launches

Eisai exec who led development of Alzheimer’s drug to retire

Bank of America ordered to pay more than $100 million for double charging fees, withholding rewards

entertainment

entertainment

hotspot

Wikipedia